Drugs that sell a lot or have a high price range will be lowered as of the 1st of next month. It will be reduced by up to 10%. It also included seven Choline alfoscerates that negotiated the redemption of drug costs for clinical revaluation. AstraZeneca's Lynparza 50mg, Kadcyla 100mg, and Kadcyla 160mg succeeded in risk-sharing contracts (RSA), respectively, with drug prices cut from 1% to 9%.

According to the industry, it will be applied as of October 1 if the revision is finalized soon. This drug price cut corresponds to the type 'Na' and 'Da' of the Price-Volume Agreement.

First of all, the type 'Na'' is a new drug which price has not been adjusted according to type 'Ka' and four years ha